| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
27,529 |
25,487 |
$2.49M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
23,519 |
22,207 |
$1.47M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,137 |
3,122 |
$311K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
2,049 |
2,024 |
$291K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
944 |
938 |
$154K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,986 |
2,921 |
$95K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,719 |
2,681 |
$65K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
903 |
894 |
$60K |
| 80053 |
Comprehensive metabolic panel |
4,875 |
4,679 |
$59K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
2,176 |
2,157 |
$50K |
| 99443 |
|
367 |
354 |
$44K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
982 |
862 |
$36K |
| 99215 |
Prolong outpt/office vis |
279 |
256 |
$35K |
| 36415 |
Collection of venous blood by venipuncture |
8,834 |
8,262 |
$33K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,952 |
1,929 |
$32K |
| 99177 |
|
905 |
900 |
$31K |
| 80061 |
Lipid panel |
2,247 |
2,154 |
$30K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,145 |
2,071 |
$29K |
| 11721 |
|
1,441 |
1,417 |
$28K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,620 |
3,448 |
$27K |
| 92587 |
|
1,060 |
1,055 |
$24K |
| S9999 |
Sales tax |
3,793 |
3,428 |
$23K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,325 |
2,238 |
$22K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
677 |
645 |
$21K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
166 |
159 |
$19K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
158 |
157 |
$17K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
587 |
581 |
$15K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
772 |
742 |
$14K |
| 99051 |
|
1,518 |
1,478 |
$14K |
| 0012A |
|
283 |
283 |
$11K |
| 0011A |
|
340 |
340 |
$11K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
100 |
100 |
$11K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
97 |
96 |
$10K |
| 90670 |
|
84 |
83 |
$10K |
| 80050 |
General health panel |
157 |
148 |
$9K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
258 |
258 |
$9K |
| 90677 |
|
67 |
63 |
$8K |
| 99072 |
|
230 |
213 |
$7K |
| 84439 |
|
590 |
560 |
$6K |
| 99441 |
|
85 |
81 |
$5K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
77 |
77 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
95 |
92 |
$4K |
| 0013A |
|
82 |
82 |
$4K |
| 0071A |
|
79 |
79 |
$3K |
| 85027 |
|
563 |
538 |
$3K |
| 96127 |
|
800 |
686 |
$3K |
| 90686 |
|
419 |
414 |
$3K |
| 11730 |
|
54 |
53 |
$3K |
| 90756 |
|
107 |
107 |
$2K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
47 |
43 |
$2K |
| 81003 |
|
1,651 |
1,583 |
$2K |
| 99080 |
|
376 |
373 |
$2K |
| 99173 |
|
65 |
64 |
$2K |
| 83721 |
|
228 |
225 |
$2K |
| 0072A |
|
38 |
38 |
$2K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
137 |
128 |
$2K |
| 84481 |
|
57 |
55 |
$1K |
| 99490 |
Ccm add 20min |
157 |
153 |
$1K |
| 90688 |
|
80 |
80 |
$1K |
| 90697 |
|
19 |
16 |
$967.11 |
| 82607 |
|
50 |
47 |
$816.79 |
| 11732 |
|
42 |
41 |
$785.43 |
| 0003A |
|
15 |
15 |
$660.76 |
| 90680 |
|
21 |
18 |
$641.66 |
| 82746 |
|
34 |
30 |
$553.34 |
| 90473 |
|
17 |
17 |
$411.64 |
| 73630 |
|
17 |
13 |
$389.09 |
| 81025 |
|
45 |
43 |
$388.72 |
| 83655 |
|
28 |
26 |
$383.14 |
| 82728 |
|
30 |
29 |
$380.01 |
| 85610 |
|
160 |
115 |
$316.67 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
26 |
26 |
$310.61 |
| 90656 |
|
12 |
12 |
$284.42 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
26 |
25 |
$274.73 |
| 93000 |
|
15 |
15 |
$265.77 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
27 |
24 |
$217.67 |
| 83540 |
|
32 |
29 |
$208.04 |
| 83550 |
|
17 |
16 |
$149.72 |
| 85651 |
|
30 |
28 |
$127.72 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
14 |
12 |
$112.44 |
| 85018 |
|
33 |
31 |
$91.02 |
| 82043 |
|
12 |
12 |
$77.25 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
108 |
106 |
$66.37 |
| 86140 |
|
13 |
13 |
$65.20 |
| 85007 |
|
13 |
13 |
$50.33 |
| G0008 |
Administration of influenza virus vaccine |
27 |
25 |
$21.00 |
| Q2035 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria) |
14 |
12 |
$20.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
31 |
31 |
$9.32 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
13 |
12 |
$7.46 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
26 |
25 |
$2.65 |
| 90685 |
|
16 |
16 |
$0.16 |
| 91300 |
|
46 |
46 |
$0.03 |
| 3075F |
|
1,051 |
989 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
132 |
130 |
$0.00 |
| 3074F |
|
6,689 |
6,217 |
$0.00 |
| 3079F |
|
2,813 |
2,601 |
$0.00 |
| 91301 |
|
506 |
506 |
$0.00 |
| 3080F |
|
619 |
561 |
$0.00 |
| 4010F |
|
40 |
30 |
$0.00 |
| G8756 |
No documentation of blood pressure measurement, reason not given |
32 |
31 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
90 |
82 |
$0.00 |
| 91307 |
|
137 |
136 |
$0.00 |
| 4050F |
|
13 |
12 |
$0.00 |
| 3078F |
|
5,188 |
4,869 |
$0.00 |
| 1160F |
|
4,924 |
4,590 |
$0.00 |
| 1159F |
|
4,914 |
4,580 |
$0.00 |
| 3077F |
|
497 |
446 |
$0.00 |
| 4004F |
|
191 |
177 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
298 |
244 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
69 |
62 |
$0.00 |
| 90672 |
|
48 |
48 |
$0.00 |
| 90633 |
|
13 |
13 |
$0.00 |
| 90710 |
|
14 |
14 |
$0.00 |
| 90671 |
|
13 |
13 |
$0.00 |